Ausgabe Sonderheft 1/2003
Inhalt (20 Artikel)
Migraine and disability: WHO's work to measure functioning, disability and health and the Global Burden of Diseases Study
Matilde Leonardi
The global burden of migraine
Richard B. Lipton, Marcelo E. Bigal, Ann I. Scher, Walter F. Stewart
Can we objectively measure the human cost of disease?
Fabio Palazzo, Giuseppe Stirparo, Lorenzo Terranova
Comorbidities of migraine: a user-friendly overview
Antonio Carolei, Irene Ciancarelli, Davide Cerone, Simona Sacco
Fixed and dynamic health-related quality of life measurements
Paola Mosconi, Giovanni Apolone
Disability and migraine: recent outcomes using an Italian version of MIDAS
Domenico D'Amico, Gennaro Bussone
General disease costing principles
Amalia Donia Sofio, Franco Mazzuca, Francesco S. Mennini
The impact of headache on quality of life
Gisela M. Terwindt, Michel D. Ferrari, Lenore J. Launer
Evaluating the economic costs of migraine: interest of a comparative approach
Jean François Dartigues, Philippe Michel, Patrick Henry
Price differentials of oral triptans in eight European Union countries
Pietro Folino-Gallo, Fabio Palazzo, Giuseppe Stirparo, Sergio De Filippis, Paolo Martelletti
Health-care systems for headache: patching the seam between primary and specialist care
Timothy J. Steiner
Reducing the costs of headache: an Italian approach
Antonietta Citterio, Grazia Sances, Giorgio Sandrini, Tiziana Repossi, Giuseppe Nappi
World Headache Alliance: raising headache awareness worldwide
Audrey Craven, Kary Shannon
Analgesic therapy for headache: consumption, appropriateness and costs
Stefania Iannazzo, Maria S. Cattaruzza, Sergio De Filippis, Flora Rossi, Edea Perata, Samanta Di Rollo, Gabriella Coloprisco, Paolo Martelletti
The prevalence of adult migraine in Calabria Region and its relationships with major sociodemographic characteristics and socio-economic impact of headache
Rosario Iannacchero, Umberto Cannistrà, Rita L. Trinchi, Antonio La Vitola, Francesco Peltrone, Emilio De Caro
Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
Giuseppe Stirparo, Fabio Palazzo, Sergio De Filippis, Paolo Martelletti